Eli Lilly And Co (NYSE:LLY)‘s stock had its “hold” rating reaffirmed by research analysts at DZ Bank in a report issued on Friday.
A number of other analysts also recently issued reports on LLY. Credit Suisse Group increased their target price on shares of Eli Lilly And Co from $82.00 to $84.00 and gave the stock an “underperform” rating in a research report on Thursday. Cantor Fitzgerald began coverage on shares of Eli Lilly And Co in a research report on Thursday, June 7th. They set an “overweight” rating and a $100.00 target price for the company. BMO Capital Markets reissued a “hold” rating and set a $78.00 target price on shares of Eli Lilly And Co in a research report on Thursday, May 10th. JPMorgan Chase & Co. set a $100.00 target price on shares of Eli Lilly And Co and gave the stock a “buy” rating in a research report on Monday, June 11th. Finally, ValuEngine raised shares of Eli Lilly And Co from a “sell” rating to a “hold” rating in a research report on Wednesday, May 23rd. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $94.00.
Shares of Eli Lilly And Co traded up $0.11, hitting $86.18, during trading hours on Friday, Marketbeat.com reports. 36,724 shares of the company were exchanged, compared to its average volume of 3,558,932. The firm has a market cap of $93.65 billion, a P/E ratio of 20.12, a PEG ratio of 1.46 and a beta of 0.29. Eli Lilly And Co has a 1 year low of $73.69 and a 1 year high of $89.09. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.41 and a quick ratio of 1.01.
In related news, SVP Susan Mahony sold 5,165 shares of the firm’s stock in a transaction on Friday, April 13th. The stock was sold at an average price of $80.14, for a total transaction of $413,923.10. Following the transaction, the senior vice president now directly owns 45,652 shares in the company, valued at $3,658,551.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction on Wednesday, April 25th. The stock was sold at an average price of $80.85, for a total value of $14,553,000.00. Following the transaction, the insider now owns 122,896,904 shares in the company, valued at $9,936,214,688.40. The disclosure for this sale can be found here. Insiders have sold 987,464 shares of company stock worth $82,748,955 over the last 90 days. 0.11% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Avestar Capital LLC bought a new stake in Eli Lilly And Co in the fourth quarter valued at $100,000. Stelac Advisory Services LLC bought a new stake in Eli Lilly And Co in the first quarter valued at $134,000. Silvant Capital Management LLC bought a new stake in Eli Lilly And Co in the first quarter valued at $150,000. McKinley Carter Wealth Services Inc. bought a new stake in Eli Lilly And Co in the first quarter valued at $153,000. Finally, Truewealth LLC bought a new stake in Eli Lilly And Co in the fourth quarter valued at $186,000. Hedge funds and other institutional investors own 76.01% of the company’s stock.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.